CONCORDBIOBSEConcord Biotech LtdMinimalNeutral
Announced Tue, 26 May · 18:36 IST

Pursuant to the regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed Annual Secretarial Compliance Report for the financial year ended ....

CONCORDBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-7.5%1-day move
₹1136.00
prior close
₹1135.10
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.4+0.2-0.1-0.3-7.5-6.9+3.9+5.3+8.7+5.1+18.3+11.7+11.4
Up moveDown movePending
AI summary

Concord Biotech has filed its Annual Secretarial Compliance Report for FY 2025-26, certified by practicing company secretary Ashish Shah. The report examined compliance with major SEBI regulations including LODR, ICDR, Takeover, PIT, and Depositories Regulations. All 12 compliance checkpoints returned a 'Yes' status, indicating full adherence to secretarial standards, timely policy updates, proper website disclosures, no director disqualifications, and compliant related party transactions. No deviations, violations, or actions by SEBI or stock exchanges were recorded during the period. No statutory auditor resignations occurred during the year.

Likely market impact

A clean compliance report with zero violations strengthens investor confidence in the company's governance standards and reduces regulatory risk. This routine filing is broadly positive but does not materially change the investment outlook.